Axogen Inc
Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porc… Read more
Axogen Inc (AXGN) - Net Assets
Latest net assets as of September 2025: $120.81 Million USD
Based on the latest financial reports, Axogen Inc (AXGN) has net assets worth $120.81 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($216.40 Million) and total liabilities ($95.59 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $120.81 Million |
| % of Total Assets | 55.82% |
| Annual Growth Rate | 8.09% |
| 5-Year Change | -15.62% |
| 10-Year Change | 1167.84% |
| Growth Volatility | 1519.41 |
Axogen Inc - Net Assets Trend (1986–2024)
This chart illustrates how Axogen Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Axogen Inc (1986–2024)
The table below shows the annual net assets of Axogen Inc from 1986 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $103.91 Million | +8.62% |
| 2023-12-31 | $95.67 Million | -5.28% |
| 2022-12-31 | $101.00 Million | -10.26% |
| 2021-12-31 | $112.55 Million | -8.61% |
| 2020-12-31 | $123.15 Million | -6.81% |
| 2019-12-31 | $132.15 Million | -10.09% |
| 2018-12-31 | $146.98 Million | +483.68% |
| 2017-12-31 | $25.18 Million | +68.77% |
| 2016-12-31 | $14.92 Million | +82.06% |
| 2015-12-31 | $8.20 Million | +172.88% |
| 2014-12-31 | $-11.25 Million | -8330.57% |
| 2013-12-31 | $136.63K | +104.83% |
| 2012-12-31 | $-2.83 Million | -146.60% |
| 2011-12-31 | $6.07 Million | -39.46% |
| 2010-12-31 | $10.03 Million | -9.33% |
| 2009-12-31 | $11.06 Million | +3431.81% |
| 2008-12-31 | $313.19K | -65.16% |
| 2007-12-31 | $898.82K | -30.69% |
| 2006-12-31 | $1.30 Million | -22.07% |
| 2005-12-31 | $1.66 Million | -27.09% |
| 2004-12-31 | $2.28 Million | +1584.11% |
| 2003-12-31 | $-153.77K | -115.90% |
| 2002-12-31 | $966.80K | -72.69% |
| 2001-12-31 | $3.54 Million | -24.99% |
| 2000-12-31 | $4.72 Million | -22.63% |
| 1999-12-31 | $6.10 Million | -27.38% |
| 1998-12-31 | $8.40 Million | -4.55% |
| 1997-12-31 | $8.80 Million | -19.27% |
| 1996-12-31 | $10.90 Million | -2.68% |
| 1995-12-31 | $11.20 Million | 0.00% |
| 1994-12-31 | $11.20 Million | +1.82% |
| 1993-12-31 | $11.00 Million | +6.80% |
| 1992-12-31 | $10.30 Million | +6.19% |
| 1991-12-31 | $9.70 Million | +10.23% |
| 1990-12-31 | $8.80 Million | +27.54% |
| 1989-12-31 | $6.90 Million | +4.55% |
| 1988-12-31 | $6.60 Million | +13.79% |
| 1987-12-31 | $5.80 Million | +7.41% |
| 1986-12-31 | $5.40 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Axogen Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 22504.6% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $441.00K | 0.42% |
| Other Components | $394.73 Million | 379.88% |
| Total Equity | $103.91 Million | 100.00% |
Axogen Inc Competitors by Market Cap
The table below lists competitors of Axogen Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CPFL Energia S.A
SA:CPFE3
|
$1.48 Billion |
|
Societatea Nationala de Transport Gaze Naturale Transgaz SA
RO:TGN
|
$1.48 Billion |
|
JUSUNG ENGINEERING Co. Ltd
KQ:036930
|
$1.49 Billion |
|
Torm PLC Class A
NASDAQ:TRMD
|
$1.49 Billion |
|
Yantai Dongcheng Pharmaceutical Co Ltd
SHE:002675
|
$1.48 Billion |
|
RED CAT HDGS INC.DL -001
F:BQ73
|
$1.48 Billion |
|
Beijing YanDong MicroElectronic Co. Ltd. A
SHG:688172
|
$1.48 Billion |
|
Shandong Humon Smelting Co Ltd
SHE:002237
|
$1.48 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Axogen Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 95,665,000 to 103,907,000, a change of 8,242,000 (8.6%).
- Net loss of 9,964,000 reduced equity.
- Other factors increased equity by 18,206,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-9.96 Million | -9.59% |
| Other Changes | $18.21 Million | +17.52% |
| Total Change | $- | 8.62% |
Book Value vs Market Value Analysis
This analysis compares Axogen Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 13.99x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 16.89x to 13.99x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1986-12-31 | $1.94 | $32.84 | x |
| 1987-12-31 | $1.68 | $32.84 | x |
| 1988-12-31 | $1.87 | $32.84 | x |
| 1989-12-31 | $1.90 | $32.84 | x |
| 1990-12-31 | $2.44 | $32.84 | x |
| 1991-12-31 | $2.52 | $32.84 | x |
| 1992-12-31 | $2.94 | $32.84 | x |
| 1993-12-31 | $3.12 | $32.84 | x |
| 1995-12-31 | $2.93 | $32.84 | x |
| 1996-12-31 | $2.87 | $32.84 | x |
| 1997-12-31 | $2.28 | $32.84 | x |
| 1998-12-31 | $2.10 | $32.84 | x |
| 1999-12-31 | $1.54 | $32.84 | x |
| 2000-12-31 | $1.21 | $32.84 | x |
| 2001-12-31 | $0.90 | $32.84 | x |
| 2002-12-31 | $0.24 | $32.84 | x |
| 2003-12-31 | $-0.04 | $32.84 | x |
| 2004-12-31 | $0.55 | $32.84 | x |
| 2005-12-31 | $0.40 | $32.84 | x |
| 2006-12-31 | $0.31 | $32.84 | x |
| 2007-12-31 | $0.22 | $32.84 | x |
| 2008-12-31 | $0.07 | $32.84 | x |
| 2009-12-31 | $2.57 | $32.84 | x |
| 2010-12-31 | $2.33 | $32.84 | x |
| 2011-12-31 | $1.64 | $32.84 | x |
| 2012-12-31 | $-0.26 | $32.84 | x |
| 2013-12-31 | $0.01 | $32.84 | x |
| 2014-12-31 | $-0.63 | $32.84 | x |
| 2015-12-31 | $0.31 | $32.84 | x |
| 2016-12-31 | $0.49 | $32.84 | x |
| 2017-12-31 | $0.76 | $32.84 | x |
| 2018-12-31 | $3.96 | $32.84 | x |
| 2019-12-31 | $3.37 | $32.84 | x |
| 2020-12-31 | $3.08 | $32.84 | x |
| 2021-12-31 | $2.73 | $32.84 | x |
| 2022-12-31 | $2.40 | $32.84 | x |
| 2023-12-31 | $2.23 | $32.84 | x |
| 2024-12-31 | $2.35 | $32.84 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Axogen Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -9.59%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -5.32%
- • Asset Turnover: 0.92x
- • Equity Multiplier: 1.96x
- Recent ROE (-9.59%) is above the historical average (-310.07%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1986 | 9.26% | 10.64% | 0.70x | 1.24x | $-40.00K |
| 1987 | 15.52% | 15.52% | 0.84x | 1.19x | $320.00K |
| 1988 | 9.09% | 9.38% | 0.11x | 8.82x | $-60.00K |
| 1989 | 5.80% | 5.88% | 0.81x | 1.22x | $-290.00K |
| 1990 | 10.23% | 11.25% | 0.84x | 1.08x | $20.00K |
| 1991 | 10.31% | 12.35% | 0.78x | 1.07x | $30.00K |
| 1992 | 6.80% | 7.61% | 0.84x | 1.07x | $-330.00K |
| 1993 | 5.45% | 5.61% | 0.84x | 1.15x | $-500.00K |
| 1995 | 1.79% | 1.42% | 1.11x | 1.13x | $-920.00K |
| 1996 | -5.50% | -4.58% | 1.07x | 1.13x | $-1.69 Million |
| 1997 | -26.14% | -18.70% | 1.04x | 1.34x | $-3.18 Million |
| 1998 | -4.76% | -3.10% | 1.22x | 1.26x | $-1.24 Million |
| 1999 | -27.87% | -13.82% | 1.40x | 1.44x | $-2.31 Million |
| 2000 | -60.58% | -19.59% | 1.72x | 1.80x | $-3.33 Million |
| 2001 | 37.95% | 8.43% | 2.51x | 1.79x | $989.47K |
| 2002 | -269.22% | -37.99% | 1.65x | 4.29x | $-2.70 Million |
| 2003 | 0.00% | -17.71% | 2.69x | 0.00x | $-1.27 Million |
| 2004 | 100.64% | 215.65% | 0.38x | 1.23x | $2.07 Million |
| 2005 | -31.89% | -119.68% | 0.24x | 1.10x | $-697.01K |
| 2006 | -28.31% | -289.90% | 0.08x | 1.17x | $-496.86K |
| 2007 | -83.33% | -745.77% | 0.09x | 1.22x | $-838.86K |
| 2008 | -332.30% | -1431.30% | 0.14x | 1.67x | $-1.07 Million |
| 2009 | 136.03% | 60.40% | 1.48x | 1.52x | $13.94 Million |
| 2010 | -13.12% | -1442.16% | 0.01x | 1.01x | $-2.32 Million |
| 2011 | -151.84% | -190.11% | 0.39x | 2.06x | $-9.83 Million |
| 2012 | 0.00% | -122.44% | 0.38x | 0.00x | $-9.14 Million |
| 2013 | -10654.00% | -132.97% | 0.40x | 202.62x | $-14.57 Million |
| 2014 | 0.00% | -105.31% | 1.03x | 0.00x | $-16.59 Million |
| 2015 | -162.97% | -48.87% | 0.73x | 4.58x | $-14.18 Million |
| 2016 | -96.58% | -35.06% | 0.89x | 3.11x | $-15.90 Million |
| 2017 | -41.48% | -17.29% | 1.03x | 2.34x | $-12.96 Million |
| 2018 | -15.24% | -26.68% | 0.52x | 1.09x | $-37.10 Million |
| 2019 | -22.04% | -27.29% | 0.69x | 1.17x | $-42.34 Million |
| 2020 | -19.31% | -21.18% | 0.56x | 1.64x | $-36.10 Million |
| 2021 | -23.98% | -21.19% | 0.61x | 1.85x | $-38.24 Million |
| 2022 | -28.66% | -20.89% | 0.71x | 1.93x | $-39.05 Million |
| 2023 | -22.70% | -13.66% | 0.81x | 2.06x | $-31.28 Million |
| 2024 | -9.59% | -5.32% | 0.92x | 1.96x | $-20.35 Million |
Industry Comparison
This section compares Axogen Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $539,803,485
- Average return on equity (ROE) among peers: -52.41%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Axogen Inc (AXGN) | $120.81 Million | 9.26% | 0.79x | $1.48 Billion |
| Advanced Biomedical Technologies Inc (ABMT) | $-7.40 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $3.67 Billion | 38.07% | 1.09x | $190.05 Billion |
| Acarix AB (publ) (ACIXF) | $1.44 Million | -102.09% | 0.28x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-13.54K | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $2.76 Million | -21.69% | 0.89x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $9.28 Million | -68.70% | 0.12x | $2.76 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $1.58 Billion | 5.73% | 1.84x | $911.62 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $11.89 Million | -17.74% | 0.30x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $456.18K | -277.12% | 2.12x | $10.62 Million |